Effect of captopril on serum lipid levels and cardiac mitochondrial oxygen consumption in experimentally-induced hypercholesterolemia in rabbits

Physiological Research

Volumn 60, Issue SUPPL.1, 2011, Pages

  Kojic, Z ^a   Gopcevic, K ^a   Marinkovic, D ^b   Tasic, G ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

ACE inhibitors; Heart; Hypercholesterolemia; Mitochondria; Oxygen consumption; Rabbits

Indexed keywords

ADENOSINE DIPHOSPHATE; BIOLOGICAL MARKER; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPID; OXYGEN;

ANIMAL; ARTICLE; BLOOD; CELL RESPIRATION; DISEASE MODEL; DRUG EFFECT; HEART MITOCHONDRION; HYPERCHOLESTEROLEMIA; MALE; METABOLISM; OXYGEN CONSUMPTION; RABBIT; SPECTROPHOTOMETRY; TIME;

ADENOSINE DIPHOSPHATE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BIOLOGICAL MARKERS; CAPTOPRIL; CELL RESPIRATION; DISEASE MODELS, ANIMAL; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MITOCHONDRIA, HEART; OXYGEN; OXYGEN CONSUMPTION; RABBITS; SPECTROPHOTOMETRY; TIME FACTORS;

EID: 84856599714     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. AL-MAGHREBI M, BENTER IF, DIZ DI. Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats. Pharmacol Res 59: 263-268, 2009.
2. ALVES AC, MEDEIROS AM, FRANCISCO V, GASPAR IM, RATO Q, BOURBON M. Molecular diagnosis of familial hypercholesterolemia: an important tool for cardiovascular risk stratification. Rev Port Cardiol 29: 907-921, 2010.
3. ALVES RJ, DIAMENT J, AMÂNCIO RF, FORTI N, MARANHÃO RC. Lack of effect of captopril on the metabolism of an artificial lipid emulsion similar to chylomicrons in hypertensive hypercholesterolemic patients. Arq Bras Cardiol 83: 512-515 (in English), 508-511 (in Portuguese), 2004.
4. BECKER RHA, WIEMER G., LINZ W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 18 (Suppl 2): S110-S115, 1991.
5. BROWN GC, BORUTAITE V. Nitric oxide and mitochondrial respiration in the heart. Cardiovasc Res 75: 283-290, 2007.
6. BROWN GC. Nitric oxide as a competitive inhibitor of oxygen consumption in the mitochondrial respiratory chain. Acta Physiol Scand 168: 667-674, 2000.
7. CHANCE B, AZZI A, LEE IY, LEE CP, MELA P. Structure and function. In: Mitochondria. L. ERNSTER, Z. DRAHOTA (eds), Academic Press, New York, NY, USA, 1969, pp 233-273.
8. CHANCE B, WILLIAMS GR. The respiratory chain and oxidative phosphorylation. Adv Enzymol 17: 54-134, 1956.
9. CHAPMAN MJ. Animal lipoproteins: chemistry, structure, and comparative aspects. J Lipid Res 21: 789-853, 1980.
10. CHEN JB, RAO BF, CHANG J, LIAO XG, CAO YD. Effects of captopril on myocardial energy metabolism in mice with viral myocarditis. (in Chinese) Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 15: 485-488, 2003.
11. CHOBANIAN AV, HAUDENSCHILD C, NICKERSON C, HOPE S. Trandolapril inhibits atherosclerosis in theWatanabe heritable hyperlipidemic rabbit. Hypertension 20: 473-477, 1992.
12. CHOLLEY BP, SHROFF SG, SANDELSKI J, KORCARZ C, BALASIA BA, JAIN S, BERGER DS, MURPHY MB, MARCUS RH, LANG RM. Differential effects of chronic oral antihypertensive therapies on systemic arterial circulation and ventricular energetics in African-American patients. Circulation 91: 1052-1062, 1995.
13. CHOWDHURY SKR, SANGLE GV, XIE X, STELMACK GL, HALAYKO AJ, SHEN GX. Effects of extensively oxidized low-density lipoprotein on mitochondrial function and reactive oxygen species in porcine aortic endothelial cells. Am J Physiol Endocrinol Metab 298: E89-E98, 2010.
14. DE CAVANAGH EM, PIOTRKOWSKI B, BASSO N, STELLA I, INSERRA F, FERDER L, FRAGA CG. Enalapril and losartan attenuate mitochondrial dysfunction in aged rats. FASEB J 17: 1096-1098, 2003.
15. DESIDERI G, GRASSI D, CROCE G, BOCALE R, TIBERTI S, EVANGELISTA S, NECOZIONE S, DI ORIO F, FERRI C. Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway. Mediators Inflamm 2008: 305087, 2008.
16. DORNAS WC, DE OLIVEIRA TT, AUGUSTO LEF, NAGEM TJ. Experimental atherosclerosis in rabbits. Arq Bras Cardiol 95: 272-278, 2010.
17. ESTABROOK RW. Mitochondrial respiratory control and the polarographic measurement of ADP:O ratios. In: Methods in Enzymology. R.W. ESTABROOK, M.E. PULLMAN (eds), Academic Press, New York, NY, USA, vol. 10, 1967, pp 41-47.
18. FRIEDEWALD WT, LEVY RI, FREDRICKSON DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502, 1972.
19. GVOZDJÁKOVÁ A, SIMKO F, KUCHARSKÁ J, BRAUNOVÁ Z, PSENEK P, KYSELOVIC J. Captopril increased mitochondrial coenzyme Q10 level, improved respiratory chain function and energy production in the left ventricle in rabbits with smoke mitochondrial cardiomyopathy. Biofactors 10: 61-65, 1999.
20. HÜNLICH M, HASENFUSS G. Effects of the NO donor sodium nitroprusside on oxygen consumption and energetics in rabbit myocardium. Basic Res Cardiol 104: 359-365, 2009.
21. JOHANNSEN DL, RAVUSSIN E. The role of mitochondria in health and disease. Curr Opin Pharmacol 9: 780-786, 2009.
22. KING CE, MELINYSHYN MJ, MEWBURN JD, CURTIS SE, WINN MJ, CAIN SM, CHAPLER CK. Canine hindlimb blood flow and O2 uptake after inhibition of EDRF/NO synthesis. J Appl Physiol 76: 1166-1171, 1994.
23. KOH KK, HAN SH, OH PC, SHIN EK, QUON MJ. Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction. Atherosclerosis 209: 307-313, 2010.
24. KOH KK, QUON MJ, HAN SH, LEE Y, KIM SJ, KOH Y, SHIN EK. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol 140: 73-81, 2010.
25. KOWALTOWSKI AJ, SEETHARAMAN S, PAUCEK P, GARLID KD. Bioenergetic consequences of opening of the ATP-sensitive K channel of heart mitochondria. Am J Physiol Heart Circ Physiol 280: H649-H657, 2001.
26. LEE SH, DOLIBA NM, OSBAKKEN MD, OZ M, MANCINI D. Improvement of myocardial mitochondrial function following hemodyanamic support with left ventricular assist devices in patients with heart failure. J Thorac Cardiovasc Surg 116: 344-349, 1998.
27. LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
28. MA A, ZHANG W, LIU Z. Effect of protection and repair of injury of mitochondrial membrane-phospholipid on prognosis in patients with dilated cardiomyopathy. Blood Press Suppl 3: 53-55, 1996.
29. MANOLIS AJ, MARKETOU ME, GAVRAS I, GAVRAS H. Cardioprotective properties of bradykinin: role of the B(2) receptor. Hypertens Res 33: 772-777, 2010.
30. MOGHADASIAN MH, FROHLICH JJ, MCMANUS BM. Advances in experimental dyslipidemia and atherosclerosis. Lab Invest 81: 1173-1183, 2001.
31. MONTECUCCO F, PENDE A, MACH F. The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediators Inflamm 2009: 752406, 2009.
32. MORAIS KL, HAYASHI MA, BRUNI FM, LOPES-FERREIRA M, CAMARGO AC, ULRICH H, LAMEU C. Bj-PRO-5a, a natural angiotensin-converting enzyme inhibitor, promotes vasodilatation mediated by both bradykinin B(2) and M1 muscarinic acetylcholine receptors. Biochem Pharmacol 81: 736-742, 2011.
33. MUJKOSOVÁ J, ULICNÁ O, WACZULÍKOVÁ I, VLKOVICOVÁ J, VANCOVÁ O, FERKO M, POLÁK S, ZIEGELHÖFFER A. Mitochondrial function in heart and kidney of spontaneously hypertensive rats: influence of captopril treatment. Gen Physiol Biophys 29: 203-207, 2010.
34. PENNA C, TULLIO F, MORO F, FOLINO A, MERLINO A, PAGLIARO P. Effects of a protocol of ischemic postconditioning and/or captopril in hearts of normotensive and hypertensive rats. Basic Res Cardiol 105: 181-192, 2010.
35. POLLARE T, LITHELL H., BERNE CH. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321: 868-873, 1989.
36. PRATT RE. Angiotensin II and the control of cardiovascular structure. J Am Soc Nephrol 10 (Suppl 11): S120-S128, 1999.
37. ROSSI MA, RAMOS SG, PRADO CM. Chronic inhibition of nitric oxide synthase induces hypertension and cardiomyocyte mitochondrial and myocardial collagen remodelling in the absence of hypertrophy. J Hypertens. 21: 993-1001, 2003.
38. SANBE A, TANONAKA K, KOBAYASI R, TAKEO S. Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril, on myocardial energy metabolism in rats with heart failure following myocardial infarction. J Mol Cell Cardiol 27: 2209-2222, 1995.
39. SCHMIEDER RE, HILGERS KF, SCHLAICH MP, SCHMIDT BM. Renin-angiotensin system and cardiovascular risk. Lancet 369: 1208-1219, 2007.
40. SHARPE N. The effects of ACE inhibition on progression of atherosclerosis. Review. J Cardiovasc Pharmacol 22 (Suppl 9): S9-S12, 1993.
41. SHEN W, HINTZE T, WOLLIN MS. Nitric oxide. an important signaling mechanisms between vascular endothelium and parenchimal cells in the regulation of oxygen consumption. Circulation 92: 3505-3512, 1995.
42. SHEN W, XU X, OCHOA M, ZHAO G, WOLIN MS, HINTZE T. Role of nitric oxide in the regulation of oxygen consumption in the conscious dogs. Circ Res 75: 1086-1095, 1994.
43. SHI L, MAO C, XU Z, ZHANG L. Angiotensin-converting enzymes and drug discovery in cardiovascular diseases. Drug Discov Today 15: 332-341, 2010.
44. VANHOUTTE PM. Regeneration of the endothelium in vascular injury. Cardiovasc Drugs Ther 24: 299-303, 2010.
45. VAVRÍNKOVÁ H, TUTTEROVÁ M, STOPKA P, DIVISOVÁ J, KAZDOVÁ L, DRAHOTA Z. The effect of captopril on nitric oxide formation and on generation of radical forms of mitochondrial respiratory chain compounds in ischemic rat heart. Physiol Res 50: 481-489, 2001.
46. WILLIAMS JG, RINCON-SKINNER T, SUN D, WANG Z, ZHANG S, ZHANG X, HINTZE TH. Role of nitric oxide in the coupling of myocardial oxygen consumption and coronary vascular dynamics during pregnancy in the dog. Am J Physiol Heart Circ Physiol 293: H2479-H2486, 2007.
47. YANAGISHITA T, TOMITA M, ITOH S, MUKAE S, ARATA H, ISHIOKA H, GESHI E, KONNO N, KATAGIRI T. Protective effect of captopril on ischemic myocardium. Jpn Circ J 61: 161-169, 1997.
48. ZENG D, ZHENG QS, OU DB. Triglyceride-mediated pathways and coronary heart disease. Lancet 376: 957, 2010.